TABLE 2.

Time-kill kinetic data for IBZ, FDX, and VAN against C. difficile isolates^a

		Drug concentration (µg/mL)
Test strain	Drug	0	4	8	16	32	64
CD630	IBZ	.	−2.22	−2.82	−2.22	−2.4	−2.75
	FDX	.	−3.52	−3.57	−3.57	−3.14	−4.01
	VAN	.	1.45	−0.08	−0.68	−1.72	−2.52
	Control	2.92	.	.	.	.	.
R20291	IBZ	.	−1.61	−1.94	−3.43	−3.94	−2.74
	FDX	.	−3.53	−4.25	−4.45	−1.92	−2.7
	VAN	.	2.53	−1.18	−2.61	−2.13	−2.1
	Control	2.27	.	.	.	.	.
FDXR28	IBZ	.	−0.68	−1.9	−0.98	−0.77	−1.04
	FDX	.	2.29	2.56	2.56	2.64	1.26
	Control	2.55	.	.	.	.	.
MT5094	IBZ	.	−3.6	−3.73	−2.92	−3.13	−3.55
	VAN	.	3.09	2.74	2.77	1.52	−1.44
	Control	2.72	.	.	.	.	.

^a Results represent the change in log₁₀ CFU/mL relative to 0 h (initial concentration). CD630 and R20291 are laboratory C. difficile strains. FDXR28 is a fidaxomicin non-susceptible isolate, and MT5094 is a vancomycin non-susceptible isolate.